Jim Cramer's Top Takeaways: Axovant Sciences, AmerisourceBergen, Isis Pharmaceuticals

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.

AXON Price Chart
AXON Price data by YCharts

Axovant Sciences (AXON) : In an exclusive interview, Cramer sat down with Vivek Ramaswamy, president and CEO of Axovant, the biotech company whose IPO rallied over 99% in today's session on high hopes for the company's Alzheimer's treatments.

Ramaswamy said that while no one still fully understands how dementia in Alzheimer's patients really works, Axovant's drug, RVT-101, which it acquired from GlaxoSmithKline (GSK) , is a unique drug that has shown amazing promise so far in Phase II testing and could potentially help millions of patients.

Ramaswamy continued by said that the drug, which is a once-a-day pill, has proven to be well tolerated and has improved both cognition and function in participants in the Phase II study. He expects to begin a six-month Phase III study later in 2015.

ABC Chart
ABC data by YCharts

AmerisourceBergen (ABC) : Cramer said this wholesale drug distributor has seen its shares up 22% so far in 2015 and they've doubled over the past two years.

Amerisource has partnerships with both Walgreens Boots Alliance (WBA) and Express Scripts (ESRX) , two stocks Cramer owns for his charitable trust, Action Alerts PLUS.

Walgreens owns 5% of Amerisource, with the option to buy up to 23% of the company. Cramer said he thinks Walgreens could consider gobbling all of the company as consolidation in the health care group runs rampant.

In addition to its core drug distribution business, Amerisource also has a lucrative specialty pharmacy division as well as consulting, veterinary medication and even a courier service. The company has a 50% market share for oncology drugs and is gaining ground in other areas as well.

Amerisource increased revenue by 14.8% in its most recent quarter to $32.7 billion and has a $1 billion share repurchase program. Cramer called the company a steal at current levels.

ISIS Chart
ISIS data by YCharts

Isis Pharmaceuticals (ISIS) : In his second interview, Cramer checked in with Dr. Stanley Crooke, founder, chairman and CEO of Isis, a stock that's up more than 106% in the last year.

Crooke provided an update to his company's Phase II study for spinal muscular atrophy, or SMA, type one, the most severe form of the disease. He explained the disease, which affects newborns, causes a disconnection between muscles and the nerves that control them. Thus, babies afflicted with SMA typically don't live more than a few months.

However, with Isis' treatment, babies were rolling over, sitting up and grasping objects, a marked improvement.

Crooke took a cautious tone, however, saying that while the company is extremely encouraged by the results, they "haven't proven anything yet." He would only say the Phase III study will prove if the drug is working or not, although he remains optimistic.

To read a full recap of "Mad Money" on CNBC, click here.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in ESRX and WBA.

More from Opinion

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook

PayPal Strikes Again, Facebook, and AT&T -- 3 Tech Stories You Must Know

PayPal Strikes Again, Facebook, and AT&T -- 3 Tech Stories You Must Know